Tag Archives: mrk

Bristol Sinks On Lung Cancer Data; Merck Up On 2 Trials

Big pharmas Merck (MRK) and Bristol-Myers Squibb (BMY) released new data on their hot new immunotherapy cancer drugs Friday afternoon, but the results sent their stocks in opposite directions. Bristol’s stock dropped 6.6% after the release of two late-breaker abstracts on studies of its drug Opdivo, a PD-1 inhibitor, for the American Society of Clinical Oncology (ASCO) meeting that opened Friday and will continue through the weekend. The study

Puma Crashes, Roche Rises On Cancer Data News

Puma Biotechnology (PBYI) stock tumbled Thursday after the company released disappointing data late Wednesday, ahead of the annual American Society for Clinical Oncology meeting. The ASCO abstract release also featured positive but somewhat conflicting news on new immuno-oncology drugs from Roche (RHHBY), AstraZeneca (AZN) and Merck (MRK). Puma issued results of its late-stage trial of breast-cancer drug neratinib, whose earlier results were so

Merck Jumps, United Therapeutics Drops On Q1 Earnings

Big pharma Merck’s stock jumped 5% Tuesday as the company’s first-quarter earnings beat estimates, bolstered by good news on its diabetes franchise. At the same time, big biotech and IBD 50 stock United Therapeutics fell 5.2% as its quarter missed views. Merck (MRK) reported earnings of 85 cents a share, down 3% from the year-earlier quarter but 10 cents better than analyst views. Sales shrank 8% to $9.43 billion but beat consensus by nearly $400